Skip to main content

Table 2 Antimicrobial resistance rates (%) of Escherichia coli isolates of patients with female genital tract infection

From: Risk factors and molecular features of sequence type (ST) 131 extended-Spectrum-β-lactamase-producing Escherichia coli in community-onset female genital tract infections

Antimicrobial agent Total (n = 91) ESBL (n = 18) Non-ESBL (n = 73) ST131a (n = 20) O25b-ST131 (n = 14) Non-ST131 (n = 71)
Ampicillin 67 (61/91) 100 (18/18) 59 (43/73) 85 (17/20) 79 (11/14) 62 (44/71)
Ampicillin/sulbactam 27 (25/91) 33 (6/18) 26 (19/73) 20 (4/20) 21 (3/14) 30 (21/71)
Piperacillin 65 (59/91) 100 (18/18) 56 (41/73) 85 (17/20) 79 (11/14) 59 (42/71)
Piperacillin/Tazobactam 0 (0/91) 0 (0/18) 0 (0/73) 0 (0/20) 0 (0/14) 0 (0/71)
Cefuroxime 25 (23/91) 94 (17/18) 8 (6/73) 40 (8/20) 36 (5/14) 21 (15/71)
Cefotaxime 25 (23/91) 94 (17/18) 7 (5/73) 40 (8/20) 36 (5/14) 20 (14/71)
Ceftazidime 24 (22/91) 94 (17/18) 7 (5/73) 40 (8/20) 36(5/14) 20 (14/71)
Cefoxitin 7 (6/91) 6 (1/18) 7 (5/73) 5 (1/20) 7 (1/14) 7 (5/71)
Cefepime 22 (20/91) 100 (18/18) 3 (2/73) 35 (7/20) 29 (4/14) 18 (13/71)
Aztreonam 22 (20/91) 94 (17/18) 4 (3/73) 35 (7/20) 29 (4/14) 18 (13/71)
Meropenem 0 (0/91) 0 (0/18) 0 (0/73) 0 (0/20) 0 (0/14) 0 (0/71)
Doripenem 0 (0/91) 0 (0/18) 0 (0/73) 0 (0/20) 0 (0/14) 0 (0/71)
Imipenem 0 (0/91) 0 (0/18) 0 (0/73) 0 (0/20) 0 (0/14) 0 (0/71)
Ciprofloxacin 36 (33/91) 67 (12/18) 29 (21/73) 40 (8/20) 50 (7/14) 35 (25/71)
Levofloxacin 30 (27/91) 61 (11/18) 22 (16/73) 40 (8/20) 50 (7/14) 27 (19/71)
Gentamicin 25 (23/91) 33 (6/18) 23 (17/73) 25 (5/20) 21 (3/14) 25 (18/71)
Tobramycin 18 (16/91) 22 (4/18) 16 (12/73) 15 (3/20) 14 (2/14) 18 (13/71)
Amikacin 1 (1/91) 0 (0/18) 1 (1/73) 0 (0/20) 0 (0/14) 1 (1/71)
Cotrimoxazole 40 (36/91) 44 (8/18) 38 (28/73) 45 (9/20) 43 (6/14) 38 (27/71)
Tigecycline 0 (0/91) 0 (0/18) 0 (0/73) 0 (0/20) 0 (0/14) 0 (0/71)
Colistin 0 (0/91) 0 (0/18) 0 (0/73) 0 (0/20) 0 (0/14) 0 (0/71)
  1. aST131 Sequence type131 (both O25 and O16), O25b Serogroup O25b, O16 Serogroup O16, ESBL, ESBL-producer; non-ESBL; non-ESBL producer